Gracell Biotechnologies Inc. (GRCL) Tops Q2 EPS by 1c

Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q2 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Studio City International Holdings Limited (MSC) Reports Q2 Loss of $0.02